FK506 Requires Stimulation of the Extracellular Signal-Regulated Kinase 1/2 and the Steroid Receptor Chaperone Protein p23 for Neurite Elongation

Bruce G. Golda,b Yong-Ping Zhonga

aCenter for Research on Occupational and Environmental Toxicology, and bDepartment of Cell and Developmental Biology, Oregon Health and Science University, Portland, Oreg., USA

Abstract
The immunosuppressant drug FK506 (tacrolimus) accelerates nerve regeneration in vivo and increases neurite elongation in vitro. We have proposed that the mechanism involves binding to the FK506-binding protein 52, a chaperone component of mature steroid receptor complexes, and a subsequent ‘gain-of-function’ involving p23 dissociation from Hsp-90 in the complex and extracellular signal-regulated kinase (ERK) activation. Here, we tested the involvement of the ERK and p23 in neurite elongation by FK506 in human SH-SY5Y cells. FK506 (10 nM) increased ERK1/2 phosphorylation at 12 and 24 h, eliciting a 3.5-fold increase at 24 h, which was inhibited in a concentration-dependent manner by an antibody (JJ3) to recombinant human p23. Neurite elongation by FK506 (10 nM), determined by measuring neurite lengths at 96 and 168 h, was completely blocked by the mitogen-activated protein kinase inhibitor PD 098059 (10 μM) and prevented, in a concentration-dependent fashion, by the p23 antibody. Taken together, the results demonstrate the functional role for ERK and p23 in the neurite elongation activity of FK506 and reveal a novel signal transduction pathway involving p23 activation of ERK. We suggest that compounds that stimulate or mimic p23 may be useful for accelerating nerve regeneration.

Introduction
FK506 (tacrolimus) is an immunosuppressant drug widely used to prevent rejection of organs [29, 50, 51] and tissue, including nerve and hand grafts [10, 32, 37]. The drug also accelerates nerve regeneration in animals [24, 25, 36, 58] and in human hand transplantations [10, 32; for a review, see ref. 18]. While immunosuppression is dependent on both calcineurin inhibition and binding to the FK506-binding protein 12 (FKBP-12) [for reviews, see ref. 13, 49], the findings that nonimmunosuppressant derivatives of FK506 that do not inhibit calcineurin nor bind to FKBP-12 retain the neurotrophic activity [7, 20, 27, 52, 53] reveal that the mechanism eliciting an increase in nerve regeneration is distinct from that underlying immunosuppression. In contrast, our studies [14, 17, 23, 26] indicate an involvement of FKBP-52, a chaperone/heat shock protein that comprises mature steroid receptor complexes [39, 42, 54].
The mature steroid receptor complex consists of the steroid hormone-binding receptor and three chaperone components: an immunophilin (FKBP-52, FKBP-51 or cyclophilin 40), Hsp-90 and p23 [6, 31]. FKBP-52 is bound to Hsp-90 via their tetratricopeptide repeat domains [6], and Hsp-90, which binds directly to the steroid hormone-binding receptor, also binds p23 [47]; FKBP-52 appears to also bind to the steroid hormone-binding component [47]. The only known function for p23 is that its binding to Hsp-90 is essential for maintaining the steroid hormone-binding component in a conformation enabling high-affinity binding for the ligand [8, 9, 11]. Upon ligand binding, the chaperone proteins dissociate from the complex, enabling the steroid hormone-binding component to bind to steroid response elements and, thereby, activating transcription. Hsp-90 binding compounds (i.e., geldanamycin and radicicol) also prevent p23 from binding to Hsp-90 [41], but reduce transcriptional activation [43].

Based on the similar neurite elongating activities of geldanamycin [23] and radicicol [16, 19, 44], we proposed that dissociation of p23 from Hsp-90 in the mature steroid receptor complex (rather than classical activation of steroid response elements) is the key event in the ability of these different classes of compounds to increase neurite elongation/nerve regeneration [17, 23, 26]. Furthermore, following its dissociation from the steroid receptor complex [17, 26], Hsp-90 may activate the mitogen-activated protein kinase pathway through its known interaction with Raf and the mitogen-activated protein kinase kinase (MEK) [40, 45], a signal transduction pathway known to be involved in neurite outgrowth [48]. Whether p23 is also able to activate the mitogen-activated protein kinase pathway remains unexplored.

Thus, in the present study, we examined the roles of extracellular signal-regulated kinase (ERK) and p23 in mediating the ability of FK506 to increase neurite elongation in human neuroblastoma SH-SY5Y cells. Preliminary reports of a portion of this work have been presented [15, 16, 19–22].

Materials and Methods

SH-SY5Y Human Neuroblastoma Cells

SH-SY5Y human neuroblastoma cells were maintained in Dulbecco’s modified Eagle’s medium (F12; Gibco) supplemented with 15% fetal calf serum (HyClone), 50 IU/ml of penicillin and 50 mg/ml streptomycin (Gibco) at 37°C with 5% CO₂. Cells were plated in six-well plates (Falcon) at 15,000 cells/well and treated with 0.4 μM aphidicolin (DNA polymerase inhibitor; Sigma). At 5 days, cells were washed, treated with nerve growth factor (NGF; 10 ng/ml), to induce process outgrowth, in the presence or absence of FK506 (10 nM). PD 098059 (10 μM) was added along with the NGF and FK506 for Western blot studies or 48 h later for neurite elongation studies. For p23 antibody studies, the cells (as above) were permeabilized by cotreatment with saponin (15 μg/ml) for 10 min in the presence of an IgG1 antibody (J33) to recombinant human p23 (Affinity BioReagents, Inc.) at 200–1,600 ng/ml, and (after 10 min) replaced with fresh medium without saponin but with the J33 antibody. All treatments were run in duplicate and the experiments repeated twice.

Western Blots

SH-SY5Y cells were collected at 12 and 24 h following treatment. To reduce ERK phosphorylation to baseline levels, fetal calf serum was not added during the last 12 h of treatment. Following treatment, the cells were washed twice with ice-cold phosphate-buffered saline, sonicated for 15 s on ice, and then heated at 100°C for 5 min. Protein concentrations in each sample were determined using the Bradford dye-binding procedure (BioRad, Richmond, Calif., USA). Equal amounts of protein (20 μg) were applied to a 10% SDS-PAGE gel and the proteins transferred to a nitrocellulose membrane. The blotted membranes were pretreated with Tris-buffered saline containing 5% nonfat milk and 0.1% Tween-20 for 1 h at room temperature, followed by a primary antibody specific to phospho-ERK (Santa Cruz Biotechnology, Inc., Santa Cruz, Calif., USA) or to total ERK (Promega, Madison, Wisc., USA) at 1:1,000 overnight at 4°C, and visualized by horseradish peroxidase-conjugated goat antirabbit or goat antimouse secondary antibody (BioRad, Richmond, Calif., USA). Values are mean ± SEM.

Neurite Elongation Measurements

For analysis of process length, cells (20 fields per well) were randomly photographed at 96 and 168 h. Neurite lengths were measured on photographic prints (final magnification ×360) using a Summa-Sketch III (Summa graphics) digitizing tablet and Bioquant Classic 95 software (R&M Biometrics, Nashville, Tenn., USA); only those processes greater than twice the cell body length were measured. For the p23 dose-dependency study, the 1,200 ng/ml and 1,600 ng/ml data (which were obtained from a separate experiment) were normalized to the FK506 level in that experiment and these values are presented with the other data shown in figure 3a.

Statistical Analysis

Values from duplicate wells were not significantly different from each other and the values for each treatment groups were combined. Mean values were compared using a one-way analysis of variance followed by Newman-Keuls multiple comparison test for comparison of individual values (WINKS 4.62, TexaSoft, Cedar Hill, Tex., USA). Values are mean ± SEM.

Results

FK506 Increases ERK1/2 Phosphorylation

We examined whether FK506, at a concentration that maximally stimulates neurite outgrowth in human SH-SY5Y cells [23], increases ERK phosphorylation. In pre-
FK506 increases ERK phosphorylation (activation). a Representative Western blots showing phosphorylated ERK1 and ERK2 (p-ERK1 and p-ERK2) and total ERK levels at 24 h after no treatment (NT) or treatment with NGF only, NGF + FK506, or NGF + FK506 and the MEK inhibitor PD 098059. FK506 (10 nM), in the absence of serum, increases phosphorylated ERK (primarily ERK2 at 24 h) levels specifically (total ERK is unaltered) compared with NGF alone, which is prevented by PD 098059. Equal amounts of protein (20 µg) were applied to each lane. b Mean values (averaged from three experiments) showing relative increase in signal intensity for the bands at 24 h, expressed as a percentage of no treatment (no serum, no NGF) control values. Signal intensity was detected using a GS-363 phosphorimager and Molecular Analysis software (see Materials and Methods). *p < 0.05, compared with other treatment groups.

**Neurite Elongation by FK506 Is Functionally Dependent upon ERK Stimulation**

We next asked whether ERK stimulation is functionally required for FK506 to increase neurite elongation in human SH-SY5Y cells. Since NGF stimulates ERK (fig. 1), which is required for the initial stages of the activity of NGF [57, 59], we were concerned that inhibition of ERK would impair the action of NGF, secondarily inhibiting the activity of FK506. As opposed to the Western blot studies (see above), this issue arose since longer periods of exposure (96–168 h) are needed to assess neurite elongation [23].

To ensure that we were studying the dependence of FK506 on ERK and not merely its dependence on NGF, we first developed a protocol whereby PD 098059 would not inhibit the neurite outgrowth activity of NGF. We found that PD 098059 did not inhibit neurite elongation at 96 h (data not shown) and 168 h (fig. 2) when given 48 h after NGF treatment. In contrast, PD 098059, when added 48 h after addition of FK506 and NGF, completely prevented the ability of FK506 to stimulate neurite elongation, reducing mean neurite lengths to those observed with NGF alone (fig. 2); the PD 098059 compound also prevented neurite elongation by several nonimmunosuppressant FK506 derivatives (data not shown), demonstrating that the requirement for ERK activation is, like nerve regeneration, independent of calcineurin inhibition [27, 52, 53].

**Neurite Elongation by FK506 Is Functionally Dependent upon p23**

p23 is an essential component of mature steroid receptor complexes, being necessary for maximal binding affinity of the steroid ligand [9, 11]. Our working hypothesis [20, 23] is that neurite elongation/nerve regeneration by steroid hormones, neuroimmunophilin ligands (e.g.
Fig. 2. The MEK inhibitor PD 098059 inhibits neurite elongation by FK506. Mean neurite lengths in SH-SY5Y cells at 168 h shown for no treatment, and NGF only and NGF + FK506 in the presence or absence of PD 098059 at two concentrations. The MEK inhibitor completely inhibits the neurite outgrowth activity of FK506 (reducing it to NGF only levels), being somewhat (albeit not significantly) more effective at the higher concentration (10 vs. 0.1 μM). In contrast, the PD 098059 compound, added 48 h after NGF, does not inhibit the activity of NGF alone. Similar results were obtained in two replicate experiments. *p < 0.05, compared with NGF only.

Fig. 3. A p23 antibody (JJ3) inhibits neurite elongation by FK506. Mean neurite lengths in SH-SY5Y cells at 168 h shown for no treatment, and NGF only, and NGF + FK506 in the presence or absence of the p23 antibody at 5 concentrations (200, 400, 800, 1,200 and 1,600 ng/ml). At 800 ng/ml, the p23 antibody completely inhibits the neurite outgrowth activity of FK506 (reducing it to NGF only levels). At higher concentrations (1,200 and 1,600 ng/ml), the antibody is even more effective, reducing neurite outgrowth below NGF only levels. For antibody penetration, the cells were permeabilized by cotreatment with saponin (15 μg/ml) for 10 min. Similar results were obtained in two replicate experiments. *p < 0.05, compared with NGF only and all p23 antibody-treated groups; †p < 0.05, compared with p23 antibody at 200 ng/ml. ‡p < 0.05, compared with p23 antibody at 200, 400 and 800 ng/ml and NGF only. Inset: controls showing lack of effect of saponin treatment on NGF-induced neurite elongation (compare NGF and NGF + saponin) and failure of a mouse IgG antibody to alter NGF-induced (left) and FK506-induced (right) neurite elongation.

Light micrographs showing representative SH-SY5Y cells treated with NGF + FK506 in the absence (top) or presence (bottom) of the p23 antibody. Note that the processes from cells treated with the p23 antibody (800 ng/ml) appear shorter in length and appear jagged and more beaded (arrowheads) compared with those not treated with the antibody. Magnification ×120.
Fig. 4. A p23 antibody (JJ3) inhibits the ability of FK506 to increase ERK phosphorylation (activation). a Representative Western blots showing phosphorylated ERK1 and ERK2 (p-ERK1 and p-ERK2) and total ERK levels at 24 h after no treatment or treatment with NGF + FK506, or NGF + FK506 and the p23 antibody (Ab) at 800 ng/ml (left). FK506 (10 nM), in the absence of serum, increases phosphorylated ERK levels compared with NGF alone, which is prevented by the p23 antibody. As a control (right), the p23 antibody (800 ng/ml) does not inhibit NGF-induced p-ERK1 and p-ERK2 (compared with NGF only). Equal amounts of protein (20 μg) were applied to each lane. b Mean values (averaged from three experiments) showing relative increase in signal intensity for the bands at 12 h, expressed as a percentage of corresponding mean NGF values. Signal intensity was detected using a GS-363 phosphorimager and Molecular Analysis software (see Materials and Methods). t-ERK = Total ERK. * p < 0.05, compared with other treatment groups.

FK506), or Hsp-90 binders (geldanamycin, radicicol) is mediated by a ‘gain-of-function’ (involving ERK activation) following dissociation of the steroid receptor complex (namely, dissociation of p23 from Hsp-90). Thus, we asked whether an antibody to p23 would prevent neurite elongation by FK506 to examine the involvement of p23.

To address this issue in human SH-SY5Y cells, we used an IgG1 antibody (JJ3) to recombinant human p23 (Affinity BioReagents, Inc.). The SH-SY5Y cells were permeabilized with saponin (15 μg/ml, for 10 min) to get the antibody into the cells; saponin alone had no effect on neurite elongation (fig. 3a, inset; see also Gold et al. [23]). We found that the p23 antibody (JJ3) markedly reduced neurite elongation by FK506 at 96 h (data not shown) and 168 h (fig. 3a) in a concentration-dependent fashion. By 168 h, neurite elongation activity of the drug was completely prevented (i.e., reduced to NGF levels) by JJ3 at 800 ng/ml and was reduced below NGF levels at a higher (1,200 ng/ml) concentration of the p23 antibody (fig. 3a); no further reduction was observed using the antibody at a concentration of 1,600 ng/ml (fig. 3a). As a control, a mouse IgG antibody did not inhibit neurite elongation by NGF or FK506 (fig. 3a, inset). In addition, the JJ3 antibody did not decrease the activity of NGF (data not shown). Interestingly, at 168 h, the neurites treated with the antibody appeared jagged and more beaded (fig. 3b), suggesting rapid retraction of the processes and, perhaps, a blockade in fast axonal transport. It should be noted that overall neurite lengths were longer, and the effect of FK506 (relative to NGF) less, in this experiment compared with the ERK study (fig. 2). This difference can be attributed to the greater spontaneous outgrowth (compare ‘no treatment’ groups in fig. 2, 3b) in this batch of cells.

Increased ERK1/2 Phosphorylation by FK506 Is Inhibited by p23 Antibody

Since the p23 antibody prevented the neurite elongation activity of FK506, we next explored whether there is a link between p23 and ERK activation. We found that the JJ3 antibody at 800 ng/ml (i.e., the concentration that completely inhibited the neurite outgrowth activity of FK506; see fig. 3a) correspondingly completely inhibited the FK506-induced increase in ERK phosphorylation at 12 (not shown) and 24 h (fig. 4a, b, left). As a control, the p23 antibody did not inhibit NGF-induced phosphorylated ERK expression demonstrating its selectivity for FK506-mediated activity (fig. 4a, b, right).
Discussion

The mechanism by which FK506 (neuroimmunophilin ligands) increases neurite elongation/nerve regeneration is unclear. Our previous studies have implicated the involvement of steroid receptor chaperone proteins via the immunophilin FKBP-52 [17, 20, 23]. The present study supports and extends this model by further revealing that neurite elongation by FK506 is dependent on both ERK activation (phosphorylation) and p23, but calcineurin independent. Furthermore, our findings indicate a link between p23 and ERK activation.

This is the first demonstration that ERK is involved in producing neurite elongation by FK506. ERK activation is important for neurite outgrowth induced by neurotrophic factors, including NGF [2, 3, 55, 57, 59; for a review, see ref. 33] and neurotrophin-3 [1]. Studies of functional involvement of the ERK pathway that rely on the PD 098059 compound need to be interpreted with caution as many studies [see, for example, ref. 4, 30, 34] are based on the use at high (30–75 μM) concentrations that are not selective for MEK [Ed Hall, Pfizer Global Development, pers. commun.]. Thus, the ability of a relatively low (10 μM) concentration of PD 098059, which is selective for MEK, to inhibit the activity of FK506 definitively demonstrates the involvement of ERK in the action of FK506. Furthermore, an increase in ERK activation could explain the protective action of FK506 from apoptosis induced by serum withdrawal in SH-SY5Y cells [38] and may play a role in its calcineurin-independent neuroprotective effect [28, 46].

While the neurotrophic activity of FK506 is clearly dependent on ERK activation, the direct upstream activator of ERK in this pathway is unknown. Hsp-90 (which binds p23) has recently been shown to directly activate Ras and MEK [40, 45]. In addition, the present study indicates that p23 also activates ERK via a FK506-dependent, but NGF-independent, pathway. One possible explanation is that release of p23 from Hsp-90 allows Hsp-90 activation of ERK and that the p23 antibody prevents its release from Hsp-90, thereby preventing ERK activation.

Alternatively, p23 may directly activate ERK after dissociation from Hsp-90 independently of Hsp-90. To explore this issue further, we are currently examining whether the Hsp-90 binders (i.e., geldanamycin and radicicol), which release p23 from Hsp-90 [41], also increase ERK phosphorylation and whether this is prevented by Hsp-90 and/or p23 antibodies. It will also be important to directly study the physiological consequences resulting from overexpressing p23 (to test whether it increases neurite elongation and ERK activation) or expressing a dominant-negative form of p23 (to test whether it inhibits neurite elongation by FK506). The ultimate downstream mediators of increased neurite elongation are unknown but may include altered gene expression (e.g. c-jun, GAP-43), regulation of the dynamics of cytoskeletal elements and insertion of new membrane into the growth cone [17, 20, 23, 26]. The ability of relatively high concentrations of the p23 antibody to inhibit neurite elongation below NGF levels is reminiscent of our previous finding using the FKBP-52 antibody [23] and suggests cross-talk with the known ability of NGF to activate the ERK pathway [17, 20, 26].

Finally, the present results provide the first demonstration of a physiological role for p23. To date, only two molecular functions are known for p23. First, it is essential for maintaining, via its binding to Hsp-90, the steroid binding domain of the mature steroid receptor complex in a conformation that has high affinity for the ligand [8, 9, 11]. Second, a very recent paper [12] demonstrates that p23 can block transcriptional activation of steroid hormone response elements. Our findings reveal a previously unknown function of p23 in activating ERK and regulating neurite elongation. Given its ubiquitous presence in nonneuronal cells with steroid receptors, it is likely that p23 functions as a universal regulator in cell growth.

Regardless of the underlying mechanism involved, the present study strongly implicates p23 as a novel target for the development of compounds that increase neurite elongation. Compounds that increase p23 expression or small molecules that are structurally similar to p23 should be developed as potential drug candidates for nerve regeneration.

Acknowledgements

We thank Brandon Bogardus and Sandra A. Gold for technical assistance, and Dan Austin for preparation of the figures.


Note added in proof
A recent publication by Price, Yamaji and Matsuoka [Br J Pharmacol 2003;140:825–829] reports similar, albeit not independent, findings since the concept and protocols (including the 48-hour delayed treatment with the MEK inhibitor) were developed by me prior to when Dr. Yamaji was a visiting scientist in my laboratory (B.G.G.).